[Boost and hypofractionation in DCIS]

[Article in German]

Affiliations

¹ Klinik für Strahlentherapie Kiel, UKSH, Kiel, Deutschland. juergen.dunst@uksh.de.
² Klinik für Strahlentherapie Kiel, UKSH, Kiel, Deutschland.

Comment

[Article in German]

Jürgen Dunst et al. Strahlenther Onkol. 2022 Dec.

. 2022 Dec;198(12):1122-1124.

doi: 10.1007/s00066-022-02016-y. Epub 2022 Oct 20.

¹ Klinik für Strahlentherapie Kiel, UKSH, Kiel, Deutschland. juergen.dunst@uksh.de.
² Klinik für Strahlentherapie Kiel, UKSH, Kiel, Deutschland.

No abstract available

Comment on

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TTT, Muanza TM, Neal A, Olivotto IA; BIG 3–07/TROG 07.01 trial investigators. Chua BH, et al. Lancet. 2022 Aug 6;400(10350):431-440. doi: 10.1016/S0140-6736(22)01246-6. Lancet. 2022. PMID: 35934006 Clinical Trial.

1. Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16:47–56. doi: 10.1016/S1470-2045(14)71156-8. - DOI - PubMed
1. Chua BH, Link EK, Kunkler IH, et al. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet. 2022;400:431–440. doi: 10.1016/S0140-6736(22)01246-6. - DOI - PubMed
1. Coles CE, Chatterjee S, Jagsi R, Kirby AM. Breast radiotherapy for ductal carcinoma in situ: could less be more? Lancet. 2022;400:408–411. doi: 10.1016/S0140-6736(22)01381-2. - DOI - PubMed
1. Early Breast Cancer Trialists’ Collaborative Group Overview of the randomised trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;41:162–177. doi: 10.1093/jncimonographs/lgq039. - DOI - PMC - PubMed
1. Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Version 4.4. von Juni 2021. https://www.awmf.org/uploads/tx_szleitlinien/032-045OLl_S3_Mammakarzinom.... Zugriff 9. Sept. 2022